View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by University of Huddersfield Repository

1 **Evaluation of Minor Groove Binders (MGBs) as novel anti-mycobacterial agents, and**
2 **the effect of using non-ionic surfactant vesicles as a delivery system to improve their**
3 **efficacy**

4 Lerato HLAKA[1,2]†, Michael-Jon ROSSLEE[1,2]†, Mumin OZTURK[1,2], Santosh KUMAR[1,2], Suraj
5 P. PARIHAR[1,2], Frank BROMBACHER[1,2], Abedawn I. KHALAF[3], Katharine C. CARTER[4],
6 Fraser J. SCOTT[5], Colin J. SUCKLING[3], Reto GULER[1,2 *]

7 [1] University of Cape Town, Institute of Infectious Diseases and Molecular Medicine (IDM),
8 Division of Immunology and South African Medical Research Council (SAMRC) Immunology
9 of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town
10 7925, South Africa.

11 [2] International Centre for Genetic Engineering and Biotechnology, Cape Town Component,
12 Cape Town 7925, South Africa.

13 [3] WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, 295
14 Cathedral Street, Glasgow G1 1XL, United Kingdom.

15 [4] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, 161
16 Cathedral Street, Glasgow, G4 ORE, United Kingdom.

17 [5] Department of Biological Sciences, University of Huddersfield, Queensgate, Huddersfield
18 HD1 3DH, UK.

19 *Corresponding author. Tel: +27-21-4066033; Fax: + 27-86-6407594
20 E-mail: reto.guler@uct.ac.za
21

22 †Both authors contributed equally to this work.

23
24 Running title: Non-ionic surfactant vesicles to deliver Minor Groove Binders intracellularly for
25 *M. tuberculosis* sterilization

26

27 **ABSTRACT**

27 **Objectives:** The slow development of major advances in drug discovery for the treatment of
28 *Mycobacterium tuberculosis* (*Mtb*) infection have led to a compelling need for evaluation of
29 more effective drug therapies against tuberculosis. New classes of drugs are constantly
30 being evaluated for anti-mycobacterial activity with currently a very limited number of new
31 drugs approved for TB treatment. Minor Groove Binders (MGBs) have previously revealed
32 promising anti-microbial activity against various infectious agents; however have not yet
33 been screened against *Mtb*.

34 **Methods:** Mycobactericidal activity of 96 MGB compounds against *Mtb* was determined
35 using H37Rv-GFP microplate assay. MGB hits were screened for their intracellular
36 mycobactericidal efficacy against clinical Beijing *Mtb* strain HN878 in bone marrow-derived
37 macrophages using standard colony-forming unit counting. Cell viability was assessed by
38 CellTiter-Blue assays. Selected MGB were encapsulated into non-ionic surfactant vesicles
39 (NIVs) for drug delivery system evaluation.

40 **Results:** H37Rv-GFP screening yielded a hitlist of 7 compounds at an MIC_{99} between 0.39
41 and 1.56 μM. MGB-362 and MGB-364 displayed intracellular mycobactericidal activity
42 against *Mtb* HN878 at MIC_{50} of 4.09 μM and 4.19 μM respectively, whilst being non-toxic.
43 Subsequent encapsulation into NIVs demonstrated a 1.6 and 2.1-fold increased intracellular
44 mycobacterial activity, similar to that of rifampicin when compared to MGB alone formulation.

45 **Conclusions:** MGBs anti-mycobacterial activities together with non-toxic properties indicate
46 that MGB compounds constitute an important new class of drug/chemical entity, which holds
47 promise in future anti-TB therapy. Furthermore, NIVs ability to better deliver entrapped MGB
48 compounds to an intracellular *Mtb* infection has provided merit for further preclinical
49 evaluation.

50

Introduction

Mycobacterium tuberculosis (*Mtb*), the causative agent of tuberculosis (TB), has become the top infectious killer worldwide. According to the 2016 World Health Organization (WHO) Global Tuberculosis Report,[1] TB killed approximately 1.8 million people in 2015, up from 1.5 million deaths in 2014.[2] The current six-month treatment regimen for drug-susceptible *Mtb*, although still effective in most cases, is gradually becoming ineffective due to increasing resistance against the drugs used to treat TB.[3] Several advances have been made in the field of TB drug discovery, spearheaded by global partnerships. For example, the Global Alliance for TB Drug Development currently manages the largest array of novel anti-TB drug compounds and novel regimens for MDR and XDR TB.[4] Other initiatives to eradicate TB include the STOP TB partnership that includes an international working group to develop new TB drugs.[5] Furthermore, several large consortia of pharmaceutical companies (TB Drug Accelerator) and academia (MM4TB) drive the discovery of new TB drugs.[6] Despite the progress in the pipeline for new diagnostics, drugs, regimens, and vaccines, research remains relentlessly underfunded. As a consequence, only a few new drugs have been approved for clinical use, i.e. delamanid, bedaquiline and pretomanid, and only ten new drugs are in advanced phases of clinical trials as of 2016.[7, 8] With the slow development of major advances in anti-mycobacterial drug discovery and the emergence of multi-drug-and extremely drug-resistant TB, there is an urgent need for the development of more effective therapies and formulations of existing drugs for the treatment of TB.[8, 9] In the area of novel therapeutics discovery, progress has been made in developing new drug classes such as benzothiazinones, which inhibit cell wall arabinan synthesis, and imidazopyridines, which inhibit respiratory chain ATP synthesis.[10, 11] Minor Groove Binder compounds (MGBs) have revealed promising antibacterial properties, but have not yet been investigated for their anti-mycobacterial activity against *Mtb in vitro.*

Derived from the natural product distamycin, MGBs are a class of compounds that selectively bind to the minor groove of bacterial DNA with their helical structure matching

78 that of DNA.[12] Most often, proteins binding to bacterial DNA bind to the major groove,
79 leaving the minor groove exposed and thus, a vacant target for MGBs. Natural forms of
80 MGBs are currently used in clinical treatment of disease. For example, aromatic diamidines,
81 such as pentamidine,[13, 14] and berenil,[15] known to bind to the minor groove at adenosine-
82 thymine tracts, have been administered clinically against human African trypanosomiasis
83 and *Pneumocystis carinii* pneumonia.[16-18] MGBs display a wide variety of activity profiles
84 against many infectious organisms evaluated, including Gram-positive bacteria,[19]
85 *Mycobacterium aurum,*[20] chloroquine sensitive and resistant *Plasmodium falciparum,*[21] and
86 *Trypanosoma brucei brucei.*[17] In partnership with MGB-Biopharma, one MGB compound has
87 successfully completed phase I clinical trials for the treatment of *Clostridium difficile*
88 infections.[22] We recently screened a limited number of MGBs for their anti-mycobacterial
89 activity against the laboratory *Mtb* H37Rv strain with MIC_{99} reaching 3.1 uM.[23] We have now
90 further extended this work by producing more active MGBs with higher MIC_{99} values against
91 *Mtb* H37Rv. In addition we examined the anti-mycobacterial activity of MGBs against
92 intracellular clinical HN878 Beijing strain of *Mtb* and evaluated the effect of MGBs exposure
93 on cell viability in macrophages.
94 Oral drug administration has various limitations such as drug inefficiency resulting
95 from drug insolubility caused by gastric low pH or poor absorbance in the gastrointestinal
96 tract. However, an effective drug delivery system can improve drug retention at the site of
97 infection. Therefore, an ability to deliver the drug to the site of infection may provide a
98 sustained drug concentration enabling increased effectiveness of a drug against its target. In
99 the case of pulmonary TB treatment, oral drug administration leads to high systemic
100 concentrations of the drugs with associated side effects such as liver toxicity and
101 cytotoxicity, amongst others.[24] Ultimately, the drawbacks associated with the oral
102 administration of antibiotics laid the foundation for the development of innovative drug
103 delivery approaches. The use of liposomes as a drug delivery system has been previously
104 reported to reduce microbial drug resistance through faster drug delivery and increasing the
105 antimicrobial drug concentration thereby preventing microbial drug efflux pump activity.[25]

106 Liposome encapsulated drugs kill microbes faster before microbial mutations can develop.
107 For example the incorporation of the antibiotic levofloxacin into liposomes improved the anti-
108 mycobacterial activity to kill *Mtb* strain resistant to levofloxacin.[26] Other drug delivery
109 systems such as non-ionic surfactant vesicles (NIV) have the ability to encapsulate both
110 hydrophobic and hydrophilic drugs for direct delivery to the site of infection.[27] NIVs are small
111 colloidal particles made of a non-aqueous, non-ionic surfactant bilayer that surrounds a
112 central aqueous compartment. They are thermodynamically stable, easily manufactured and
113 do not require special storage conditions. One of the major advantages of NIVs is that they
114 are able to entrap different types of drug substances and can have their size altered. Their
115 capacity to improve the delivery of small molecules is an important trait that allows for
116 precise targeting of deposition of particles within the respiratory tract. Previous studies have
117 shown NIVs to be a promising inhalable drug delivery system against pulmonary
118 aspergillosis with aerosolized amphotericin B (AMB)-NIV administration reducing fungal lung
119 burden when compared to AMB solution only.[28] More recent studies are showing
120 antibacterial action of moxiflacin[29] and cefixime[30] and antiviral action of nevirapine[31] in NIV
121 formulations. Although many different drug delivery systems have been utilised to entrap
122 first-line TB drugs,[32] only a few have systematically explored their anti-mycobacterial activity
123 against *Mtb* and against intracellular *Mtb* in infected primary macrophages. Thus, we have
124 investigated the use of NIVs as a drug delivery system on the improvement of delivery and
125 efficacy of novel MGB compounds to *Mtb*-infected macrophages.

Materials and methods

Minor Groove Binder compounds

MGB compounds were synthesized using distamycin template, a natural product with known infective properties as previously reported.[17, 23, 33] Alterations of the head, tail, side chains and body resulted in a number of diverse compounds with later synthesis driven by acquired screening data (Table S1). MGBs were re-suspended in DMSO to a concentration of 1.25 mM and were stored at -80˚C.

Preparation of compounds and non-ionic surfactant vesicles

MGB compounds (Stock: 1.25 mM) and rifampicin (Stock: 20 mM) were diluted to a starting concentration of 50 µM followed by 2-fold dilutions in 7H9 broth medium or DMEM to yield required screening range. Freeze dried NIVs were prepared as previously described[28] and rehydrated in DMEM + 10% FCS (Gibco, Thermofisher Scientific, USA) to a NIV concentration range of 23-5000 µM (empty NIV) and subsequently added to bone marrow-derived macrophages (BMDMs) in order to assess cell viability through CellTiter-Blue (Promega, Wisconsin, USA) assay with fluorescence detection at ($544_{ex}/590_{em}$ nm). Subsequently, drug-NIV solutions were prepared in DMEM + 10% FCS at 2:5 molar ratio (MGB: NIV) at compound two-fold serial dilution range from 1.56 to 12.5 µM (3.91-31.25 µM NIV) to assess cell viability and intracellular anti-mycobacterial activity. Two-fold serial drug dilution was performed as previously reported in other drug screening studies.[34]

H37Rv-GFP microplate screening assay

MGB compounds were screened for their anti-mycobacterial activity using 96-well, black clear flat-bottom microplates (Greiner Bio-One, Germany) as previously reported.[35, 36] Single cell suspension of H37Rv-GFP from frozen stock with working concentration of $1x10^6$ cfu/mL, was prepared in Middlebrook 7H9 supplemented with 25 mg/l kanamycin, 10% Middlebrook OADC (v/v) and 0.05% tween 80 (w/v). 100 µL of H37Rv-GFP at a

153 concentration of 1x10^5 cfu/well was added to each experimental well. 100 μL of drug
154 compounds prepared in 7H9 broth supplemented with 25 mg/L kanamycin to generate
155 0.195-50 μM screening range, was added to well containing H37Rv-GFP for final screening
156 range of 0.0977-25 μM. Wells containing compound only at the highest screening
157 concentration were used to detect autofluorescence of compounds and broth (vehicle
158 control). Fluorescence (485_{ex} /520_{em} nm) was measured at designated time points; days 0, 4,
159 8, 10 and 12 with BMG Labtech Omega Plate Reader (Germany). The addition of sterile
160 water to the outer wells of each plate served to minimize the evaporation. Time intervals
161 were selected as previously reported in other drug screening studies.[36]
162

163 ***Bone marrow-derived macrophages generation and Mtb infection***

164 BMDMs were generated from 8-12 week old C57BL/6 mice as previously reported.[37] After
165 differentiation, BMDMs were plated into 96-well plates (Nunc, Denmark) at 2 x 10^5 cells per
166 well. Following overnight adherence, BMDMs were then infected with *Mtb* HN878 (MOI=5)
167 and cultured at 37˚C under 5% CO_2 for 4 hours. BMDMs were washed once with pre-
168 warmed culture media to remove extracellular bacteria or lysed and lysates plated on 7H10
169 agar plates supplemented with 10% OADC and 0.5% glycerol for cfu counting to determine
170 bacilli uptake. Drug compounds prepared in DMEM media supplemented with 10% FCS at
171 defined concentrations were added to infected BMDMs to determine anti-mycobacterial
172 activity and cell viability. After 5 days of culture, cells were lysed for cfu plating or assessed
173 for cell viability by CellTiter-Blue assay.
174

175 ***Statistical analysis***

176 All data were analysed using R, a student t-test (two-tailed with equal variance) or unless
177 otherwise stated in figure legends. A $^*p$ value of less 0.05 was considered significant, with
178 $^{**}p < 0.01$ and $^{***}p < 0.001$.

179 # Results

180 ## *Minimum inhibitory concentration (MIC_{99}) of MGB compounds against H37Rv-*

181 ## *GFP*

182 We screened 96 MGBs for their anti-mycobacterial activity against GFP-labelled H37Rv *Mtb*
183 in liquid broth culture using a 96-well plate assay (Table 1). Relative fluorescence was
184 measured at 0, 4, 8, 10 and 12 days in broth culture of MGBs (serially diluted from 25 μM to
185 0.19 μM) to determine the minimum inhibitory concentration (MIC_{99}) of MGBs required to
186 eradicate 99% of *Mtb* (Figure 1). Hit compounds, defined as previously reported,[38] were
187 identified as drugs that were active at or below the threshold concentration of 3.12 μM. A
188 hitlist of 7 compounds were identified with an MIC_{99} of 1.56 μM or less (Figure 1 and Table
189 1). Rifampicin, which had an MIC of 0.0977 μM, was used as the positive control. The
190 selected hit compounds were MGBs 362, 368, 361, 365, 359, 364 and 367 with MIC_{99} range
191 (0.391-1.56 μM) and therefore were identified for subsequent intracellular anti-
192 mycobactericidal activity screening.

193

194 ## *Intracellular drug activity against clinical Mtb and macrophage cell viability*

195 The ability of anti-TB drug compounds to penetrate macrophages and induce
196 mycobactericidal activity, while being non-toxic to the macrophages, is a salient property
197 sought after in TB drug development. Hence, BMDMs were exposed to serial MGB drug
198 concentrations from 1.56 to 12.5 μM to evaluate their anti-mycobacterial activity against the
199 clinical *Mtb* strain HN878, after 5 days of infection. Compounds were screened for the
200 concentration which eradicated 50% of bacilli (MIC_{50}, Figure 2A). Two of the 7 hit
201 compounds identified from screening studies against *Mtb* in Figure 1 had good intracellular
202 mycobacterial killing efficacy against *Mtb*-infected macrophages, with MIC_{50} values of 4.09
203 μM (MGB 362) and 4.19 μM (MGB 364). Rifampicin, selected as a positive control, had a
204 MIC_{50} of 1.7 μM. CellTiter-Blue cell viability assay was performed to assess for macrophage

205 cell viability in MGBs-treated BMDMs after 5 days of exposure (Figure 2B). MGB 362 and
206 364 and rifampicin had no significant effect on macrophage viability at the respective
207 intracellular drug activity MIC_{50} concentrations (Figure 2B). These data suggests that MGB
208 362 and 364 have an efficient intracellular anti-mycobacterial activity against *Mtb* while being
209 non-toxic to the host cells.
210

211 ***MBGs-NIV encapsulation increased intracellular drug activity against clinical***
212 ***strain of Mtb***

213 We next investigated whether encapsulating our hit MGB compounds into NIVs, a drug
214 delivery system that was previously reported to improve drug delivery of amphotericin B to
215 macrophages,[28] would improve MGBs drug efficacy against the intracellular clinical HN878
216 *Mtb* strain. We demonstrated that encapsulating MGBs into NIVs improved the intracellular
217 anti-mycobacterial abilities by 2.1-fold for MGB 362, and 1.6-fold for MGB 364 in *Mtb*
218 HN878-infected BMDMs, displaying a significant cfu reduction ($P < 0.01$) compared to
219 controls (Figure 3A). The anti-mycobacterial killing activity of MGB 362-NIV and MGB 364-
220 NIV were similar to that of rifampicin. MGB-NIV 364 displayed a significant decreased cfu
221 counts ($P < 0.033$) when compared to MGB alone. Furthermore, *Mtb*-infected macrophages
222 were viable following MGB-NIV treatment (Figure 3B). Treatment with NIV-alone also had no
223 significant effect on macrophage viability (data not shown). These results demonstrate that
224 NIVs can act as a suitable delivery system by transporting MGB inside macrophages, the
225 target cells for *Mtb*.

Discussion

MGB compounds have shown great potential for their use as antibacterial therapeutic agents.[33] However, their activity against *Mtb* remains unknown. Here, we demonstrated the anti-mycobacterial (MIC_{99}) properties of MGBs against *Mtb* (H37Rv-GFP) with a reliable screening method that enables the detection of most active compounds,[39] using rifampicin as a positive control. All of the active MGB compounds belong to the well-established alkene-linked minor groove binder family discovered at the University of Strathclyde with high killing activities against different pathogens as previously reported.[17, 19-21, 23, 33] Since the primary binding sites of all of these MGBs in the DNA minor groove are AT rich regions it is unlikely that target sequence specificity is responsible for the selectivity observed. This is true also for the active compounds against *Mtb* described here. However, it is more likely that activity and selectivity against a particular pathogen is caused by differential access to cells caused by differing cell wall and cell membrane structures in a way that with the current state of knowledge is idiosyncratic and unpredictable.[33] What can be reliably stated is that the alkene-linked compounds are significantly the most biologically active of the Strathclyde MGB family. In general, MGBs with the most significant antibacterial activity possess a range of different tail groups, all of which are exemplified within the set in our screen. However, all of the most active MGBs identified in this study possess an amidine-containing tail group, which perhaps suggests an important role of tail group pKa for targeting mycobacteria.

Screening of MGB compounds in the context of their cell viability and anti-mycobacterial activity against intracellular clinical *Mtb* strain HN878 have identified two compounds with promising results, giving a hit rate of 2.1% (2/96). In most studies the hit rate for hit compounds is in the order of 1%, in-line with previous studies.[40] These findings however warrant *in vivo* testing which aims to allow for better clinical therapeutic translation of the findings. The use of non-ionic surfactant vesicles (NIVs) has been demonstrated repeatedly in literature before and constitutes a prominent focus within current *Mtb* research in order to combat the infection.[27, 41] NIVs given by nebulisation delivered amphotericin B to

253 the lungs and liver with significantly improved treatment outcome when compared to AMB
254 solution against pulmonary aspergillosis and visceral leishmaniasis.[28] Our investigation of
255 NIVs as a delivery device indeed demonstrate that NIVs can be used to enhance the efficacy
256 of MGB compounds against HN878 in infected BMDMs whilst not increasing the toxicity of
257 the drug to BMDMs. MGB contain hydrophobic head groups[12] which allows for encapsulation
258 into NIV. Liposomes have previously been reported to encapsulate an alkyl derivative of
259 distamycin A[42] which are naturally occurring backbones for MGB compound synthesis.

260 NIVs ability to trap the drug within its hydrophilic/-phobic compartment allows the
261 drug to be taken up by phagocytosis by the infected macrophage, thereby transporting the
262 drug to the site of infection. Using NIV drug formulations resulted in higher drug levels
263 compared to similar treatment with drug solution at the site of infection after treatment by the
264 pulmonary or intravenous routes for water soluble[43, 44] and lipid soluble drugs[28]. Studies in
265 dogs treated by the intravenous route with a sodium stibogluconate-dextran (SSG)-NIV
266 formulation increased the elimination half-life and the volume of distribution at steady state
267 compared to SSG-dextran solution.[45] Therefore NIV-MGB formulation can be a feasible
268 pulmonary treatment for *Mtb*.

269 In conclusion, this study showed that MGBs constitute an important new class of
270 drug/chemical entity with favourable anti-mycobacterial activity and holds promise in future
271 anti-TB therapy. Furthermore, we demonstrate that NIVs contribute to better delivery of
272 drugs to an intracellular infection and secondly act as a delivery device for entrapped MGB
273 compounds and lastly serve as the initial step into future research of targeted delivery of
274 entrapped drug to *Mtb*-infected cells.

275 ## Acknowledgements

276 We thank Ms. Fadwah Booley, Ms. Lorna Gcanga and Mr. George Jacobs for their excellent
277 technical assistance.

278

279 ## Funding

280 This work was supported by the Knowledge Exchange Development Fund (KEDF) from the
281 University of Strathclyde to KCC, the International Centre for Genetic Engineering &
282 Biotechnology (ICGEB) Arturo Falaschi PhD Fellowship to MO and SK, the Claude Leon
283 Foundation and CIDRI, Wellcome trust (Grant No. 084323) post-doctoral fellowships to SPP,
284 the South African Medical Research Council (SAMRC) doctoral fellowship to LH, grants from
285 the South African National Research Foundation (NRF) and from the Department of Science
286 and Technology, South African Research Chair Initiative (SARCHi) and South Africa Medical
287 Research Council (SAMRC) to FB, grants from the Department of Science and Technology
288 (DST) / South African National Research Foundation (NRF) Collaborative Postgraduate
289 Training Programme to RG.

290

291 ## Transparency Declarations

292 None to declare.

293 **References**

294 1. WHO. Global tuberculosis report 2016. Geneva: World Health Organization.
295 http://www.who.int/tb/publications/global_report/en/
296 2. WHO. Global tuberculosis report 2015. Geneva: World Health Organization.
297 http://www.who.int/tb/publications/global_report/gtbr15_main_text.pdf
298 3. Zumla A, Abubakar I, Raviglione M *et al.* Drug-resistant tuberculosis-current dilemmas,
299 unanswered questions, challenges, and priority needs. *J Infect Dis* 2012; **205 Suppl 2**: S228-40.
300 4. Murray S, Mendel C, Spigelman M. TB Alliance regimen development for multidrug-resistant
301 tuberculosis. *Int J Tuberc Lung Dis* 2016; **20**: S38-S41.
302 5. Mwaba P, McNerney R, Grobusch MP *et al.* Achieving STOP TB Partnership goals:
303 perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. *Trop Med Int*
304 *Health* 2011; **16**: 819-27.
305 6. Zuniga ES, Early J, Parish T. The future for early-stage tuberculosis drug discovery. *Future*
306 *Microbiol* 2015; **10**: 217-29.
307 7. Pai M, Behr MA, Dowdy D *et al.* Tuberculosis. *Nat Rev Dis Primers* 2016; **2**: 16076.
308 8. Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pipeline and
309 emerging drug targets. *Cold Spring Harb Perspect Med* 2015; **5**.
310 9. Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant
311 tuberculosis: clinical utility of bedaquiline and delamanid. *Infect Drug Resist* 2015; **8**: 367-78.
312 10. Pethe K, Bifani P, Jang J *et al.* Discovery of Q203, a potent clinical candidate for the
313 treatment of tuberculosis. *Nat Med* 2013; **19**: 1157-60.
314 11. Makarov V, Manina G, Mikusova K et al. Benzothiazinones kill *Mycobacterium tuberculosis*
315 by blocking arabinan synthesis. *Science* 2009; **324**: 801-4.
316 12. Suckling CJ. Molecular recognition and physicochemical properties in the discovery of
317 selective antibacterial minor groove binders. *J Phys Org Chem* 2008; **21**: 575-83.
318 13. Edwards KJ, Jenkins TC, Neidle S. Crystal structure of a pentamidine-oligonucleotide
319 complex: implications for DNA-binding properties. *Biochemistry* 1992; **31**: 7104-9.
320 14. Fox KR, Sansom CE, Stevens MFG. Footprinting studies on the sequence-selective binding of
321 pentamidine to DNA. *FEBS Letters* 1990; **266**: 150-4.
322 15. Brown DG, Sanderson MR, Garman E *et al*. Crystal structure of a berenil-d(CGCAAATTTGCG)
323 complex. *J Mol Biol* 1992; **226**: 481-90.
324 16. Paine MF, Wang MZ, Generaux CN *et al.* Diamidines for human African trypanosomiasis. *Curr*
325 *Opin Investig Drugs* 2010; **11**: 876-83.
326 17. Scott FJ, Khalaf AI, Giordani F *et al.* An evaluation of Minor Groove Binders as anti-
327 *Trypanosoma brucei brucei* therapeutics. *Eur J Med Chem* 2016; **116**: 116-25.
328 18. Tao B, Huang TL, Zhang Q *et al.* Synthesis and anti-*Pneumocystis carinii* activity of
329 conformationally restricted analogues of pentamidine. *Eur J Med Chem* 1999; **34**: 531-8.
330 19. Khalaf AI, Bourdin C, Breen D *et al.* Design, synthesis and antibacterial activity of minor
331 groove binders: the role of non-cationic tail groups. *Eur J Med Chem* 2012; **56**: 39-47.
332 20. Khalaf AI, Anthony N, Breen D *et al.* Amide isosteres in structure-activity studies of
333 antibacterial minor groove binders. *Eur J Med Chem* 2011; **46**: 5343-55.
334 21. Scott FJ, Khalaf AI, Duffy S et al. Selective anti-malarial minor groove binders. *Bioorg Med*
335 *Chem Lett* 2016; **26**: 3326-9.
336 22. Ravic M, Firmin D, Sahgal O *et al*, 2016. *A Single-Centre, Double-Blind, Placebo-Controlled*
337 *Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of*
338 *MGB-BP-3, a New Class of Antibacterial Agent*. American Society of Microbiology Microbe Meeting,
339 Boston, Massachusetts, USA.
340 23. Scott FJ, Nichol RJ, Khalaf AI *et al.* An evaluation of minor groove binders as anti-fungal and
341 anti-mycobacterial therapeutics. *Eur J Med Chem* 2017; **136:** 561-72.

342 24. Gulbay BE, Gurkan OU, Yildiz OA *et al.* Side effects due to primary antituberculosis drugs
343 during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. *Respir Med* 2006;
344 **100**: 1834-42.
345 25. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial
346 resistance. *Adv Drug Deliv Rev* 2013; **65**: 1803-15.
347 26. Gaidukevich SK, Mikulovich YL, Smirnova TG *et al.* Antibacterial Effects of Liposomes
348 Containing Phospholipid Cardiolipin and Fluoroquinolone Levofloxacin on *Mycobacterium*
349 *tuberculosis* with Extensive Drug Resistance. *Bull Exp Biol Med* 2016; **160**: 675-8.
350 27. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug
351 delivery—an overview. *Acta Pharmaceutica Sinica B* 2011; **1**: 208-19.
352 28. Alsaadi M, Italia JL, Mullen AB *et al.* The efficacy of aerosol treatment with non-ionic
353 surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary
354 aspergillosis infection. *J Control Release* 2012; **160**: 685-91.
355 29. Sohrabi S, Haeri A, Mahboubi A *et al*. Chitosan gel-embedded moxifloxacin niosomes: An
356 efficient antimicrobial hybrid system for burn infection. *Int J Biol Macromol* 2016; **85**: 625-33.
357 30. Imran M, Shah MR, Ullah F et al. Glycoside-based niosomal nanocarrier for enhanced in-vivo
358 performance of Cefixime. *Int J Pharm* 2016; **505**: 122-32.
359 31. Mehta SK, Jindal N. Tyloxapol niosomes as prospective drug delivery module for
360 antiretroviral drug nevirapine. *AAPS PharmSciTech* 2015; **16**: 67-75.
361 32. Hari BN, Chitra KP, Bhimavarapu R et al. Novel technologies: A weapon against tuberculosis.
362 *Indian J Pharmacol* 2010; **42**: 338-44.
363 33. Barrett MP, Gemmell CG, Suckling CJ. Minor groove binders as anti-infective agents.
364 *Pharmacol Ther* 2013; **139**: 12-23.
365 34. Andreu N, Fletcher T, Krishnan N *et al*. Rapid measurement of antituberculosis drug activity
366 in vitro and in macrophages using bioluminescence. *J Antimicrob Chemother* 2011; **67**: 404-14.
367 35. Collins LA, Torrero MN, Franzblau SG. Green fluorescent protein reporter microplate assay
368 for high-throughput screening of compounds against *Mycobacterium tuberculosis*. *Antimicrob*
369 *Agents Chemother* 1998; **42**: 344-7.
370 36. Salie S, Hsu NJ, Semenya D *et al.* Novel non-neuroleptic phenothiazines inhibit
371 Mycobacterium tuberculosis replication. *J Antimicrob Chemother* 2014; **69**: 1551-8.
372 37. Schwegmann A, Guler R, Cutler AJ et al. Protein kinase C delta is essential for optimal
373 macrophage-mediated phagosomal containment of *Listeria monocytogenes. Proc Natl Acad Sci U S A*
374 2007; **104**: 16251-6.
375 38. Hughes JP, Rees S, Kalindjian SB *et al.* Principles of early drug discovery. *Br J Pharmacol* 2011;
376 **162**: 1239-49.
377 39. Changsen C, Franzblau SG, Palittapongarnpim P. Improved green fluorescent protein
378 reporter gene-based microplate screening for antituberculosis compounds by utilizing an
379 acetamidase promoter. *Antimicrob Agents Chemother* 2003; **47**: 3682-7.
380 40. Fuchs JE, Spitzer GM, Javed A *et al.* Minor groove binders and drugs targeting proteins cover
381 complementary regions in chemical shape space. *J Chem Inf Model* 2011; **51**: 2223-32.
382 41. Rajera R, Nagpal K, Singh SK *et al.* Niosomes: a controlled and novel drug delivery system.
383 *Biol Pharm Bull* 2011; **34**: 945-53.
384 42. Cortesi R, Romagnoli R, Menegatti E *et al.* Liposomes containing distamycins: preparation,
385 characterization and antiproliferative activity. *Drug Deliv* 2004; **11**: 83-8.
386 43. Carter KC, Mullen AB, Sundar S *et al.* Efficacies of vesicular and free sodium stibogluconate
387 formulations against clinical isolates of *Leishmania donovani*. *Antimicrob Agents Chemother* 2001;
388 **45**: 3555-9.
389 44. Williams D, Mullen AB, Baillie AJ *et al.* Comparison of the efficacy of free and non-ionic-
390 surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. *J*
391 *Pharm Pharmacol* 1998; **50**: 1351-6.

392 45. Nieto J, Alvar J, Mullen AB et al. Pharmacokinetics, toxicities, and efficacies of sodium
393 stibogluconate formulations after intravenous administration in animals. *Antimicrob Agents*
394 *Chemother* 2003; **47**: 2781-7.

395

Table 1. MIC_{99} of all screened MGBs against H37Rv-GFP. 7 hits were identified out of 96 MGBs screened. MGBs marked with asterisk symbols were previously screened as reported.[23]

	Compound	MIC_{99}	Compound	MIC_{99}	Compound	MIC_{99}
	Rifampicin	0.0977	**371**	25	**235**	>25
Hits	**362**	0.391	**372**	25	**245**	>25
Hits	**368**	0.391	**373**	25	**246**	>25
Hits	**361**	0.781	**374**	25	**247**	>25
Hits	**365**	0.781	**381**	25	**248**	>25
Hits	**359**	1.56	**1**	>25	**270**	>25
Hits	**364**	1.56	**2**	>25	**271**	>25
Hits	**367**	1.56	**9**	>25	**283**	>25
	353*	3.12	**12**	>25	**286**	>25
	354*	3.12	**74***	>25	**287**	>25
	391	3.12	**85**	>25	**288**	>25
	263	6.25	**92**	>25	**289**	>25
	343	6.25	**114**	>25	**300**	>25
	385	6.25	**121**	>25	**303**	>25
	386	6.25	**122**	>25	**304**	>25
	351*	12.5	**123**	>25	**305**	>25
	352*	12.5	**124**	>25	**306**	>25
	376	12.5	**131**	>25	**322**	>25
	377	12.5	**134**	>25	**323**	>25
	378	12.5	**147**	>25	**324***	>25
	379	12.5	**154**	>25	**325**	>25
	380	12.5	**176**	>25	**329***	>25
	383	12.5	**185**	>25	**331***	>25
	387	12.5	**187**	>25	**332***	>25
	390	12.5	**188**	>25	**333***	>25
	282	12.5 - 25	**192**	>25	**334***	>25
	4*	25	**210**	>25	**335***	>25
	116	25	**212**	>25	**336***	>25
	164	25	**213**	>25	**338***	>25
	292	25	**214**	>25	**356**	>25
	317*	25	**222**	>25	**357**	>25
	330*	25	**234**	>25	**358**	>25
	337	25				



Figure 1. Screening of anti-mycobacterial activity of MGB compounds against H37Rv-GFP. Direct antimicrobial activity of MGB compounds at the drug concentration range of 0.195 - 25 µM was tested against H37Rv-GFP (1×10^5 cfu/well) in 7H9 liquid broth culture using microplate assay. The anti-mycobacterial activity of MGB treatment on H37Rv-GFP was determined at a concentration-dependent manner by measuring fluorescence ($485_{ex}/520_{em}$ nm) on days 0, 4, 8, 10 and 12. Data was corrected for background 7H9 fluorescence. Data show mean ± SEM of duplicates.

A **B**

MGB 362





MGB 364





Rifampicin





Figure 2. MIC$_{50}$ of MGB compounds in HN878 *Mtb*-infected BMDMs and cell viability**.** A) The intracellular anti-mycobacterial activities of MGBs (1.5625-12.5 µM) and rifampicin (0.3906-3.125 µM) were assessed by counting cfu at the respective concentration at 5 days post Mtb HN878 infection. MIC$_{50}$ values of each drug compound were identified in GraphPad Prism by non-linear regression analysis. B) Macrophage cell viability was determined at 5 days of MGB compound exposure and measured by CellTiter-Blue assay with fluorescence detection at ($544_{ex}/590_{em}$ nm). Data were corrected for background culture medium fluorescence and are shown mean ± SEM, representative of triplicates. Two-tailed Student's t-test, *$p < 0.05$, **$p < 0.01$, *** $p < 0.001$ compared to control.

506
507
508
509
510
511
512
513
514
515
516
517
518
519
520



521 **Figure 3.** MGBs-NIV formulation intracellular mycobacterial activity in HN878 Mtb-infected
522 BMDMs and cell viability. A) The intracellular anti-mycobacterial activity of MGBs only,
523 MGBs-NIV formulation and rifampicin was determined in comparison to control (no drug
524 treatment). Cfu was determined at 5 days post Mtb HN878 infection. B) Macrophage cell
525 viability was determined at 5 days post *Mtb* HN878 infection and measured by CellTiter-Blue
526 assay with fluorescence detection at ($544_{ex}/590_{em}$ nm). Data were corrected for background
527 culture media fluorescence and are shown as show mean ± SD, representative of triplicates.
528 Two-tailed Student's t-test, *$p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared to control.